Greater improvement to vascular markers and effective cardiac function was shown in 160 T2DM patients after twelve months of an add-on treatment of metformin with GLP-1RA, SGLT2 Is, and their combination with respect to insulin [304]. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.